Nienke ter Haar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Nienke ter Haar has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Alejandra Bodelón
Center for Translational Immunology University Medical Center Utrecht, Utrecht University Utrecht The Netherlands
2 shared publications - Hisham I. Abu-Tawil
Center for Translational Immunology, University Medical Center Utrecht, 3584 EA Utrecht, The Netherlands
2 shared publications - Jorg van Loosdregt
Center for Translational Immunology, University Medical Center Utrecht, 3584 CX Utrecht, The Netherlands
2 shared publications - Lucas Wilhelmus Picavet
Center for Translational Immunology, University Medical Center Utrecht, 3584 CX Utrecht, The Netherlands
2 shared publications - Sebastiaan J. Vastert
Center for Translational Immunology, University Medical Center Utrecht, 3584 CX Utrecht, The Netherlands
2 shared publications - Arjan Boltjes
Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands
1 shared publication
Latest Publications
- Open Access
- 25 September 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (19) , 9364
Transcriptional Regulation of WTAP Isoforms by NF-κB Signaling in Human Monocytes
N6-methyladenosine (m6A) is a dynamic RNA modification that critically modulates gene expression in immune responses. While m6A regulators such as WTAP are implicated in inflammatory and autoimmune diseases, the mechanisms governing their expression during innate immune activation remain unclear. Here, we demonstrate that WTAP expression in human CD14+ monocytes is upregulated upon lipopolysaccharide (LPS) stimulation and is associated with alternative promoter usage leading to distinct mRNA isoforms. Bioinformatic analysis and pharmacological inhibition reveal that the transcription factor RELA (NF-κB pathway) directly contributes to this promoter-specific induction. Functional analyses show that both WTAP isoforms encode identical proteins, indicating transcriptional, rather than post-transcriptional, regulation. These findings uncover a novel NF-κB-dependent mechanism regulating WTAP isoform expression in activated monocytes, providing insight into the epitranscriptomic modulation of inflammation and potential dysregulation in autoimmune disease.
- 25 September 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (19) , 9364
Open AccessTranscriptional Regulation of WTAP Isoforms by NF-κB Signaling in Human Monocytes
N6-methyladenosine (m6A) is a dynamic RNA modification that critically modulates gene expression in immune responses. While m6A regulators such as WTAP are implicated in inflammatory and autoimmune diseases, the mechanisms governing their expression during innate immune activation remain unclear. Here, we demonstrate that WTAP expression in human CD14+ monocytes is upregulated upon lipopolysaccharide (LPS) stimulation and is associated with alternative promoter usage leading to distinct mRNA isoforms. Bioinformatic analysis and pharmacological inhibition reveal that the transcription factor RELA (NF-κB pathway) directly contributes to this promoter-specific induction. Functional analyses show that both WTAP isoforms encode identical proteins, indicating transcriptional, rather than post-transcriptional, regulation. These findings uncover a novel NF-κB-dependent mechanism regulating WTAP isoform expression in activated monocytes, providing insight into the epitranscriptomic modulation of inflammation and potential dysregulation in autoimmune disease.
- Open Access
- 22 September 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (18) , 9248
Reduced Expression of m6A Demethylases FTO and ALKBH5 in Monocytes from the Site of Inflammation in Patients with Juvenile Idiopathic Arthritis
N6-methyladenosine (m6A) has recently emerged as a post-transcriptional modulator governing cell-specific gene expression in innate immune cells, particularly in monocytes. Disruptions in m6A homeostasis, manifested as the altered expression of m6A-related proteins and m6A levels, have been implicated in autoimmune disorders. Perturbations in m6A dynamics within total Peripheral blood mononuclear cells (PBMCs) have shown strong correlations with disease severity in rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). It remains unclear in which specific cell type(s) m6A homeostasis is disturbed, and also whether other rheumatic diseases such as juvenile idiopathic arthritis (JIA) show similar features. Here, we assess the involvement of m6A and m6A-regulatory proteins in JIA monocytes. Notably, the diminished expression of m6A-eraser proteins FTO and ALKBH5 was observed in JIA monocytes extracted from the inflamed joint. This resulted in increased m6A-methylated transcripts in monocytes from these patients. Correspondingly, we observed that culturing monocytes in the presence of synovial fluid from JIA inflamed joints reduced the expression of both FTO and ALKBH5. The knock-out of FTO in human monocytes of healthy controls increased monocyte activation, indicating the relevance of FTO and m6A in the context of JIA. These findings underscore the potential of ALKBH5 and FTO expression as a biomarker in JIA and identify the m6A machinery as a potential therapeutic target for the treatment of JIA and possibly other autoimmune diseases in the future.
- 22 September 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (18) , 9248
Open AccessReduced Expression of m6A Demethylases FTO and ALKBH5 in Monocytes from the Site of Inflammation in Patients with Juvenile Idiopathic Arthritis
N6-methyladenosine (m6A) has recently emerged as a post-transcriptional modulator governing cell-specific gene expression in innate immune cells, particularly in monocytes. Disruptions in m6A homeostasis, manifested as the altered expression of m6A-related proteins and m6A levels, have been implicated in autoimmune disorders. Perturbations in m6A dynamics within total Peripheral blood mononuclear cells (PBMCs) have shown strong correlations with disease severity in rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). It remains unclear in which specific cell type(s) m6A homeostasis is disturbed, and also whether other rheumatic diseases such as juvenile idiopathic arthritis (JIA) show similar features. Here, we assess the involvement of m6A and m6A-regulatory proteins in JIA monocytes. Notably, the diminished expression of m6A-eraser proteins FTO and ALKBH5 was observed in JIA monocytes extracted from the inflamed joint. This resulted in increased m6A-methylated transcripts in monocytes from these patients. Correspondingly, we observed that culturing monocytes in the presence of synovial fluid from JIA inflamed joints reduced the expression of both FTO and ALKBH5. The knock-out of FTO in human monocytes of healthy controls increased monocyte activation, indicating the relevance of FTO and m6A in the context of JIA. These findings underscore the potential of ALKBH5 and FTO expression as a biomarker in JIA and identify the m6A machinery as a potential therapeutic target for the treatment of JIA and possibly other autoimmune diseases in the future.